Crina Ioana Radu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Crina Ioana Radu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adelina-Gabriela Niculescu
Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, 011061 Bucharest, Romania
2 shared publications - Alexandru Mihai Grumezescu
Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology POLITEHNICA Bucharest, 1-7 Gheorghe Polizu Street, 011061 Bucharest, Romania
2 shared publications - Daniel Mihai Teleanu
“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2 shared publications - Oana Aurelia Vladacenco
“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2 shared publications - Raluca Ioana Teleanu
“Dr. Victor Gomoiu” Clinical Children’s Hospital, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
2 shared publications - Bogdan Costăchescu
“Gr. T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 25 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (11) , 5938
An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases
Oxidative stress has been linked with a variety of diseases, being involved in the debut and/or progress of several neurodegenerative disorders. This review intends to summarize some of the findings that correlate the overproduction of reactive oxygen species with the pathophysiology of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Oxidative stress was also noted to modify the inflammatory response. Even though oxidative stress and neuroinflammation are two totally different pathological events, they are linked and affect one another. Nonetheless, there are still several mechanisms that need to be understood regarding the onset and the progress of neurodegenerative diseases in order to develop efficient therapies. As antioxidants are a means to alter oxidative stress and slow down the symptoms of these neurodegenerative diseases, the most common antioxidants, enzymatic as well as non-enzymatic, have been mentioned in this paper as therapeutic options for the discussed disorders.
- 25 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (11) , 5938
Top Cited PapersOpen AccessAn Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases
Oxidative stress has been linked with a variety of diseases, being involved in the debut and/or progress of several neurodegenerative disorders. This review intends to summarize some of the findings that correlate the overproduction of reactive oxygen species with the pathophysiology of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Oxidative stress was also noted to modify the inflammatory response. Even though oxidative stress and neuroinflammation are two totally different pathological events, they are linked and affect one another. Nonetheless, there are still several mechanisms that need to be understood regarding the onset and the progress of neurodegenerative diseases in order to develop efficient therapies. As antioxidants are a means to alter oxidative stress and slow down the symptoms of these neurodegenerative diseases, the most common antioxidants, enzymatic as well as non-enzymatic, have been mentioned in this paper as therapeutic options for the discussed disorders.
- Top Cited PapersOpen Access
- 4 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 987
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
The blood–brain barrier (BBB) has shown to be a significant obstacle to brain medication delivery. The BBB in a healthy brain is a diffusion barrier that prevents most substances from passing from the blood to the brain; only tiny molecules can pass across the BBB. The BBB is disturbed in specific pathological illnesses such as stroke, diabetes, seizures, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The goal of this study is to offer a general overview of current brain medication delivery techniques and associated topics from the last five years. It is anticipated that this review will stimulate readers to look into new ways to deliver medications to the brain. Following an introduction of the construction and function of the BBB in both healthy and pathological conditions, this review revisits certain contested questions, such as whether nanoparticles may cross the BBB on their own and if medications are selectively delivered to the brain by deliberately targeted nanoparticles. Current non-nanoparticle options are also discussed, including drug delivery via the permeable BBB under pathological circumstances and the use of non-invasive approaches to improve brain medication absorption.
- 4 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 987
Top Cited PapersOpen AccessCurrent Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
The blood–brain barrier (BBB) has shown to be a significant obstacle to brain medication delivery. The BBB in a healthy brain is a diffusion barrier that prevents most substances from passing from the blood to the brain; only tiny molecules can pass across the BBB. The BBB is disturbed in specific pathological illnesses such as stroke, diabetes, seizures, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The goal of this study is to offer a general overview of current brain medication delivery techniques and associated topics from the last five years. It is anticipated that this review will stimulate readers to look into new ways to deliver medications to the brain. Following an introduction of the construction and function of the BBB in both healthy and pathological conditions, this review revisits certain contested questions, such as whether nanoparticles may cross the BBB on their own and if medications are selectively delivered to the brain by deliberately targeted nanoparticles. Current non-nanoparticle options are also discussed, including drug delivery via the permeable BBB under pathological circumstances and the use of non-invasive approaches to improve brain medication absorption.